Is rituximab suitable for use as a first-line biologic therapy for RA?

Nature Clinical Practice Rheumatology

Volumn 4, Issue 11, 2008, Pages 574-575

  Kleiner, Anatole ^a   Looney, R John ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTHROPATHY; ARTICLE; BIOLOGICAL THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION RISK; LONG TERM CARE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 68349127529     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0905     Document Type: Article

References (8)

1. McGonagle D et al. (2008) Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) 47 865-867
2. Cohen SB et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary safety and efficacy at twenty-four weeks. Arthritis Rheum 54: 2793-2806
3. Emery P et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390-1400
4. Keystone EC et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50: 1400-1411
5. Keystone EC et al. (2008) Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis [doi:10.1136/ard.2007.085787]
6. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285
7. Looney RJ et al. (2008) The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 58: 5-14
8. Hauser SL et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688